Microarray profile of human kidney from diabetes, renal cell carcinoma and renal cell carcinoma with diabetes

Adam Kosti, Hung I.Harry Chen, Sumathy Mohan, Sitai Liang, Yidong Chen, Samy L. Habib

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Recent study from our laboratory showed that patients with diabetes are at a higher risk of developing kidney cancer. In the current study, we have screened whole human DNA genome from healthy control, patients with diabetes or renal cell carcinoma (RCC) or RCC+diabetes. We found that 883 genes gain/163 genes loss of copy number in RCC+diabetes group, 669 genes gain/307 genes loss in RCC group and 458 genes gain/38 genes loss of copy number in diabetes group, after removing gain/loss genes obtained from healthy control group. Data analyzed for functional annotation enrichment pathways showed that control group had the highest number (280) of enriched pathways, 191 in diabetes+RCC group, 148 in RCC group, and 81 in diabetes group. The overlap GO pathways between RCC+diabetes and RCC groups showed that nine were enriched, between RCC+diabetes and diabetes groups was four and between diabetes and RCC groups was eight GO pathways. Overall, we observed majority of DNA alterations in patients from RCC+diabetes group. Interestingly, insulin receptor (INSR) is highly expressed and had gains in copy number in RCC+diabetes and diabetes groups. The changes in INSR copy number may use as a biomarker for predicting RCC development in diabetic patients.

Original languageEnglish (US)
Pages (from-to)62-70
Number of pages9
JournalGenes and Cancer
Issue number1-2
StatePublished - 2015


  • Diabetes
  • Microarray
  • RCC
  • Renal

ASJC Scopus subject areas

  • Genetics
  • Cancer Research


Dive into the research topics of 'Microarray profile of human kidney from diabetes, renal cell carcinoma and renal cell carcinoma with diabetes'. Together they form a unique fingerprint.

Cite this